Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Non Operating Income (2020 - 2025)

Caribou Biosciences has reported Non Operating Income over the past 6 years, most recently at $1.4 million for Q4 2025.

  • Quarterly Non Operating Income fell 58.09% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$331000.0 through Dec 2025, down 101.89% year-over-year, with the annual reading at -$331000.0 for FY2025, 101.89% down from the prior year.
  • Non Operating Income was $1.4 million for Q4 2025 at Caribou Biosciences, down from $1.9 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $5.8 million in Q2 2024 and troughed at -$6.5 million in Q2 2025.
  • The 5-year median for Non Operating Income is $2.6 million (2021), against an average of $2.0 million.
  • Year-over-year, Non Operating Income plummeted 2940.96% in 2021 and then skyrocketed 10931.25% in 2022.
  • A 5-year view of Non Operating Income shows it stood at $2.2 million in 2021, then surged by 62.84% to $3.7 million in 2022, then decreased by 14.46% to $3.1 million in 2023, then grew by 7.86% to $3.4 million in 2024, then plummeted by 58.09% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Non Operating Income are $1.4 million (Q4 2025), $1.9 million (Q3 2025), and -$6.5 million (Q2 2025).